<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Aso on Hassan Saei</title>
    <link>https://hassansaei.github.io/tags/aso/</link>
    <description>Recent content in Aso on Hassan Saei</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <copyright>&amp;copy; 2024 Hassan Saei</copyright>
    <lastBuildDate>Tue, 30 Dec 2025 00:00:00 +0000</lastBuildDate>
    
	<atom:link href="https://hassansaei.github.io/tags/aso/index.xml" rel="self" type="application/rss+xml" />
    
    
    <item>
      <title>Splice modulation therapy development using XLAS organoid models</title>
      <link>https://hassansaei.github.io/project/organoid_aso/</link>
      <pubDate>Tue, 30 Dec 2025 00:00:00 +0000</pubDate>
      
      <guid>https://hassansaei.github.io/project/organoid_aso/</guid>
      <description>Kidney organoids are an emerging tool for disease modeling, especially genetic diseases. Among these diseases, X-linked Alport syndrome (XLAS) is a hematuric nephropathy affecting the glomerular basement membrane (GBM) secondary to pathogenic variations in the COL4A5 gene encoding the α5 subunit of type IV collagen [α5(IV)]. In patients carrying pathogenic variations affecting splicing, the use of antisense oligonucleotides (ASOs) offers immense therapeutic hope. In this study, we develop a framework combining the use of patient-derived cells and kidney organoids to provide evidence of the therapeutic efficacy of ASOs in XLAS patients.</description>
    </item>
    
  </channel>
</rss>